The evidence leans constructive7 supporting, 0 against, 0 worth knowing
Supporting
trading 37% above its 200-day average
up 10% over twelve months
matches more cash than borrowings, which has beaten the market by +1.47 points over 20 sessions across 6,919 past signals
9 of the scans it matches have a positive measured record
4 independent kinds of evidence agree today, which is uncommon
revenue grew 44% year on year in the quarter ending 30 June 2026
net margin has widened from 10.2% to 19.8% across four quarters
Against
nothing the data supports either way
Worth knowing
nothing the data supports either way
What would change this read: a close below 14, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working4
Net profit rose 123.7% year on year, from Rs 11 cr to Rs 25 cr.
+123.7%Rs 11 crRs 25 cr
Profit grew faster than revenue, +123.7% against +22.7%.
+123.7%+22.7%
Net margin moved from 10.9% to 19.8%.
10.9%19.8%
Trading 37.4% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+37.4%
Needs watching2
Pharmaceuticals Drugs & formulations is 99% of revenue, so the business rests on one segment.
Pharmaceuticals Drugs & formulations99%
A warning rule fires on it tonight: stretched far above trend.
Stretched far above trend
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 4 of these 4 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
10 of 47 matched on 10 Sep
SYNCOMF matches 10 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
segments and revenue mix, as the company reports them
SYNCOMF reports 3 business segments. The largest is Pharmaceuticals Drugs & formulations at 99% of revenue in the quarter ending 30 June 2026. On these numbers this is effectively a single-segment business, so the group result and that segment’s result move together.
SegmentRevenueSharevs a year ago
Pharmaceuticals Drugs & formulations132 cr99.2%—
Renting of Property1 cr0.6%—
Trading of Commodities0 cr0.2%—
Segment names are the company’s own, taken verbatim from the reportable-segment disclosure in its quarterly XBRL filing. Nothing on this page describes the business in words we wrote.
Quality of the business
balance sheet as at 31 March 2026
Return on equity
19.7%
trailing profit over shareholders’ funds
Return on capital
26.0%
pre-tax profit over equity plus borrowings
Debt to equity
0.00×
1 cr borrowed against 415 cr of equity
Net debt
4 cr
cash exceeds borrowings
Cash conversion
71%
operating cash flow as a share of profit
Receivable days
80
how long customers take to pay
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 26 September 2024
19×
median 39×
66×
now 22×
SYNCOMF trades at 22× trailing earnings, below its median of 39× over this window — 44% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · Management filings were typically +0.06pt vs the market over the next 5 sessions (n=2,634)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 44% against the same quarter a year earlier
profit rose 226% year on year
net margin widened from 18.6% to 19.8%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
126
32
25
0.26
19.8%
Q4 FY26
31 Mar · consolidated
135
34
25
0.27
18.6%
Q3 FY26
31 Dec · consolidated
115
25
19
0.23
16.4%
Q3 FY25
31 Dec · consolidated
128
17
13
0.14
10.2%
Q2 FY25
30 Sep · consolidated
102
15
11
0.16
10.9%
Q1 FY25
30 Jun · consolidated
87
10
8
0.11
8.7%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+24.1%
Versus 200-day average+37.4%
Below 52-week high-10.0%
Above 52-week low+87.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)65.9
Higher closes in last 51 of 5
Six-month return+60.90%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)7.68%
Volume versus 20-day0.6x
Median daily turnoverRs 20.6 cr
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
3 Sep
3
Rising on most days lately, Stretched far above trend, Short averages stacked in order
2 Sep
5
Rising on most days lately, Made a new 52-week high today, Stretched far above trend, Short averages stacked in order, Growing fast and near a high
1 Sep
1
Short averages stacked in order
31 Aug
1
Inside bar — quieter than yesterday
28 Aug
4
Rising on most days lately, Made a new 52-week high today, Short averages stacked in order, Gapped up and held it